GlassScriptPhysician profile
Helene Hubbard
NPI 1912957556
$331.90
in general payments reported to CMS, 2019-2025
9 companies · $101 in 2025
The $101 reported for 2025 was more than what a typical Developmental - Behavioral Pediatrics provider received nationally (typical 2025 total: $79.84).
See the full distribution for Developmental - Behavioral Pediatrics
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $231 · 2025: $101.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $101.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $101.06 | 2025 | |
| Ironshore Pharmaceuticals INC. | $69.77 | 2019 | |
| Glaxosmithkline, LLC. | $41.16 | 2019 | |
| Pfizer INC. | $27.14 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.19 | 2019 | |
| Neos Therapeutics, LP | $20.54 | 2019 | |
| Sobi, INC | $16.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $16.29 | 2019 | |
| Kaleo, INC. | $14.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helene Hubbard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.